On September 5, theImmune Reconstruction and Application Joint Laboratoryjointly established by Shenzhen University of Advanced Technology and Beijing Bofurui Gene Diagnostics Technology Co., Ltd. was officially unveiled.

In the future, both parties will rely on this joint laboratory, closely aligning with enterprise development needs, conducting deep cooperation in frontier technology research, new product development, technology platform construction, and talent cultivation, while jointly applying for science and technology funding projects at all levels, and focusing on effortsin directions such as“thymus function reconstruction and its applications in inducing transplant immune tolerance”to achieve breakthroughs and transformations in key technologies.

Fan Jianping, President of Shenzhen University of Advanced Technology, Kang Le, Dean of the Institute of Cell and Gene Technology, Zhao Yong, Chair Professor of the Faculty of Synthetic Biology, Liu Xiangjun, Chairman of Beijing Bofurui Gene Diagnostics Technology Co., Ltd., Liao Zhihan, Director of Public Relations, and Zhen Yan, General Manager of Guangzhou Bofurui Medical Testing Co., Ltd., jointly unveiled the joint laboratory.

Fan Jianping stated that this cooperation is a concrete practice of Shenzhen University of Advanced Technology in building a highland for technological innovation and achievement transformation. The complementary strengths between the university and Bofurui are extremely strong—Shenzhen University of Advanced Technology’s accumulation in basic research and talent reserves perfectly aligns with the company’s advantages in clinical resources and industrialization experience.“We look forward to joint efforts to build the joint laboratory into a benchmark for industry-academia-research-application in the field of immune reconstruction, not only producing high-level research results but also cultivating a group of composite talents who understand technology and clinical practice, contributing to the Healthy China strategy with the strength of Shenzhen University of Advanced Technology.”

Kang Le emphasized that immune reconstruction is a frontier field at the intersection of life sciences and medicine, and the thymus, as the “central organ” of the immune system, its breakthrough in functional reconstruction technology will drive transplant medicine from “anti-rejection” to “inducing immune tolerance.”“The Immune Reconstruction and Application Joint Laboratory is the first university-enterprise cooperative laboratory of the Institute of Cell and Gene Technology. We will integrate multidisciplinary resources, deeply collaborate with Bofurui’s clinical expert team, focus on the transformation chain from ‘lab to bedside,’ strive for original breakthroughs in thymus-related research, and provide feasible technical solutions for industry, making greater contributions to human health.”

Liu Xiangjun pointed out that Bofurui has been deeply engaged in the field of transplant medicine for over a decade, always with the vision of “enabling transplant patients to live like healthy people post-surgery.” The research strength of Shenzhen University of Advanced Technology in the field of cell and gene technology has laid a solid foundation for the cooperation between both parties.The establishment of the joint laboratory will create a stable, long-term tolerant state of life for global high-risk organ rejection and severe autoimmune disease patients, helping them return to society.

The establishment of this joint laboratory is both an important strategic move for Shenzhen University of Advanced Technology to deepen industry-academia-research integration in the field of cell and gene technology and a key initiative for Bofurui to expand technological boundaries and enhance core competitiveness. Both parties will use the joint laboratory as a fulcrum to promote immune reconstruction technology from theoretical breakthroughs to clinical applications, bringing more precise and safer treatment options to transplant patients and helping China achieve leapfrog development in the field of precision medicine.

As one of the pioneers in comprehensive transplant risk management, Bofurui has been deeply engaged in the transplant field for 20 years, possessing top-notch comprehensive capabilities and experience in China, actively practicing the integration of industry, academia, research, and application, collaborating deeply with top domestic transplant centers, and achieving multiple globally leading results in clinical and research fields. This collaboration with a globally leading immunology team, fully leveraging respective strengths, will surely provide the latest research directions and optimal solutions for transplant patients and practitioners in the transplant field.

Shenzhen University of Advanced Technology, based on the “industry-education integration, innovation-driven” development strategy, guided by market demand, has conducted extensive cooperation with partner enterprises through co-building university-enterprise joint laboratories in frontier technology research, new product development, technology platform construction, and talent cultivation, building a deeply integrated ecosystem of industry, academia, research, and application, driving efficient transformation of research results, and continuously empowering regional industrial upgrading and high-quality economic development.